Biodexa Pharmaceuticals Plc ADR (BDRX)

$2.17 +0.08 (3.83%)
Market Cap 1.42M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 109,462
Avg Vol 1,241,600
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 5%
Beta 0.95
Analysts Strong Buy
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
TATTED_KEN
TATTED_KEN Jan. 15 at 9:11 PM
$RAYA running hard AH. Same float as $BDRX
0 · Reply
acarsoy
acarsoy Jan. 15 at 5:46 PM
$BDRX keep eye on it
0 · Reply
StockGuru95
StockGuru95 Jan. 15 at 5:04 PM
$BDRX 👀 ⬆️
0 · Reply
StockGuru95
StockGuru95 Jan. 15 at 5:02 PM
$BDRX showing strong upside potential in this volatile market. Phase 3 eRapa enrollment in FAP + promising oncology pipeline. With momentum favoring high-upside, catalyst-driven names, this one could run 200%+ if sentiment turns. NFA #BDRX #Biotech #BiotechStocks #SmallCaps #PennyStocks #StockMarket #Trading #HighRiskHighReward
0 · Reply
jowzakiki
jowzakiki Jan. 15 at 1:37 PM
$BDRX
0 · Reply
ItTakesItAll
ItTakesItAll Jan. 15 at 11:05 AM
$BDRX 😉 more
0 · Reply
GATTACA2025
GATTACA2025 Jan. 15 at 4:03 AM
$BDRX It IS funny. Mo pumping for years but beaud alwats go down.lower and loser everyyear. He is banking his short while the rsvennis homelesd.
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 13 at 12:43 PM
$BDRX gave u something with sprc*
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 12 at 9:20 PM
$BDRX need to tinker with your read out this week beud !
1 · Reply
ML6
ML6 Jan. 12 at 2:52 PM
$BDRX In at 6.99. Out at 8.20. Gain of +17% We're all winners today!!!
0 · Reply
Latest News on BDRX
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 10 days ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 4 weeks ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 6 weeks ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 7 weeks ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 2 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 3 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 4 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 4 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 5 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 6 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 6 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 6 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 7 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 7 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 7 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 7 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 8 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 8 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 8 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 9 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 10 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 11 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 11 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

TATTED_KEN
TATTED_KEN Jan. 15 at 9:11 PM
$RAYA running hard AH. Same float as $BDRX
0 · Reply
acarsoy
acarsoy Jan. 15 at 5:46 PM
$BDRX keep eye on it
0 · Reply
StockGuru95
StockGuru95 Jan. 15 at 5:04 PM
$BDRX 👀 ⬆️
0 · Reply
StockGuru95
StockGuru95 Jan. 15 at 5:02 PM
$BDRX showing strong upside potential in this volatile market. Phase 3 eRapa enrollment in FAP + promising oncology pipeline. With momentum favoring high-upside, catalyst-driven names, this one could run 200%+ if sentiment turns. NFA #BDRX #Biotech #BiotechStocks #SmallCaps #PennyStocks #StockMarket #Trading #HighRiskHighReward
0 · Reply
jowzakiki
jowzakiki Jan. 15 at 1:37 PM
$BDRX
0 · Reply
ItTakesItAll
ItTakesItAll Jan. 15 at 11:05 AM
$BDRX 😉 more
0 · Reply
GATTACA2025
GATTACA2025 Jan. 15 at 4:03 AM
$BDRX It IS funny. Mo pumping for years but beaud alwats go down.lower and loser everyyear. He is banking his short while the rsvennis homelesd.
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 13 at 12:43 PM
$BDRX gave u something with sprc*
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 12 at 9:20 PM
$BDRX need to tinker with your read out this week beud !
1 · Reply
ML6
ML6 Jan. 12 at 2:52 PM
$BDRX In at 6.99. Out at 8.20. Gain of +17% We're all winners today!!!
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 12 at 1:03 PM
$BDRX WILL NEED TO DETONATE AN UPDATE IT WONT B ORGANIC BEUD *
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 12 at 12:49 PM
$BDRX CHANGED SOMETHING ON U BEUD
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 12 at 12:13 PM
$BDRX gave u something with NCEL kids
1 · Reply
DPaul5151
DPaul5151 Jan. 9 at 6:54 PM
$BDRX keep an eye on it
0 · Reply
CasualTraderAndRegard
CasualTraderAndRegard Jan. 9 at 6:48 PM
$BDRX I believe in a BDRX squeeze, here’s why TL;DR BDRX checks the main boxes squeeze traders look for: • Reported short interest is huge • Borrow is extremely expensive (hard-to-borrow) • Micro-float behavior (small share base = fast moves when volume hits) • Active Phase 3 program with near-term trial-site activation milestones that can generate legit headline momentum ⸻ 1) Squeeze setup: shorts are crowded (official SI) • Shares short (official): ~494,378 on the most recent widely-posted settlement date. • Multiple trackers frame this as very high short interest vs float. Bull takeaway: a crowded short base + rising price/volume can create forced buying (covering) into strength. ⸻
4 · Reply
StrategistBrady
StrategistBrady Jan. 9 at 5:53 PM
$BDRX can curl up
1 · Reply
ItTakesItAll
ItTakesItAll Jan. 9 at 1:44 PM
$BDRX Adding again 2.20s-2.30s, totally undervalued, imho. Let me try it again. 12/16 40%+ 5.67-8.09 12/10 75%+ 5.04-8.83 12/08 150%+ 5.95-14.93
0 · Reply
TATTED_KEN
TATTED_KEN Jan. 9 at 1:40 PM
Gave you $ICON $KUST. Adding $BDRX float 800k. Cash/sh $8.92.
1 · Reply
Love_To_Learn
Love_To_Learn Jan. 7 at 12:31 PM
$BDRX u had an update that was suppose to come yesterday that has been delayed temp*
0 · Reply
GooRich
GooRich Jan. 6 at 4:59 PM
$BDRX
0 · Reply
TATTED_KEN
TATTED_KEN Jan. 5 at 8:25 PM
$BDRX adding $2.5s
0 · Reply
DiamondPlayz
DiamondPlayz Jan. 5 at 5:47 PM
Seeing bulls rotate into PAVM now. Starting its massive run - Early positioning is key 💎 Low float tickers have been exploding 300% lately. Just 700k shares outstanding, don't miss PAVM ! $ILLR $BTC.X $KITT $BDRX :::
0 · Reply